> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Revises Covid Vaccine Composition Recommendation
- URL: https://www.fdaweb.com/fda-revises-covid-vaccine-composition-recommendation/
- Published: 2024-06-13T12:00:00.000Z
- Updated: 2026-09-14T14:33:17.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5157180

FDA is updating its advice on this fall’s Covid-19 vaccine composition based on a recent review of circulating Covid cases in the U.S. “Based on the most current available data, along with the recent rise in cases of Covid-19 in areas of the country, the agency has further determined that the preferred JN.1-lineage for the Covid-19 vaccines (2024-2025 Formula) is the KP.2 strain, if feasible,” an [FDA notice](https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024?ref=fdaweb.com) says.

Earlier this month, an FDA advisory committee unanimously voted to recommend a monovalent JN.1-lineage vaccine composition. “Following the vote, the committee discussed considerations for the selection of a specific JN.1 lineage SARS-CoV-2 strain (e.g., JN.1 or KP.2) and expressed a strong preference for JN.1,” the notice says. Based on newer data, the latest change is intended to ensure that the Covid-19 vaccines (2024-2025 Formula) more closely match circulating SARS-CoV-2 strains, it says.

FDA says it does not expect that a change to KP.2 will delay the availability of the vaccines in the U.S.